Research topics:

Personalized drug screening and risk assessment in neuroendocrine tumors of the gastroenteropancreatic and bronchopulmonary system, pheochromocytomas and paragangliomas in vitro, in vivo and using fresh patient-derived primary cultures. Identification of patient-specific, genetically-informed/cluster-dependent therapeutic strategies and discovery of risk factors for tumor progression, therapy resistance, and prognostic biomarkers (precision oncology).

Ongoing Projects:

•  Deutsche Forschungsgemeinschaft (DFG), SFB CRC-TRR-205, 3rd funding period (Co-PI Svenja Nölting): Towards Personalised Treat  ment Strategies for Aggressive PPGLs: Novel Biomarkers and Therapeutic Approaches
•  Exzellenz-Netzwerk für neuroendokrine Tumoren München (NeoExNET) registry (Co-PI Christoph J. Auernhammer) am GEPNET-KUM

Completed Projects:

• Else Kröner-Fresenius Foundation (PI Svenja Nölting): Characterisation and overcoming mechanisms of resistance to the mTORC1 inhibitor everolimus in vitro in two human pancreatic neuroendocrine tumor cell lines (BON RR1, BON RR2) with stable resistance to everolimus, in vivo in an orthotopic intrapancreatic xenograft mouse model and in human tumor tissue by utilizing signalling pathway analysis (2019-2021) 
• Novartis: Young Investigators in Neuroendocrine Neoplasia Germany Program (YING) (PI Svenja Nölting): Therapy resistance in neuroendocrine neoplasia (2019-2021)
• Radiosensitizing and somatostatin receptor re-expression in neuroendocrine tumor cells: Translational concepts for peptide receptor chemo radionuclide therapy (PRCRT) (PI Christoph J. Auernhammer & Svenja Nölting)
• Deutsche Forschungsgemeinschaft (DFG), SFB CRC-TRR-205, 1st and 2nd funding periods (Co-PI Svenja Nölting)